logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Aveo Pharmaceuticals, Inc.


USPTO Granted Patents = 42

% Expired Patents = 35.7


Trademarks = 6

Forward Citations = 163

Loading Chart...
Loading Chart...

71 inventors (with patents filed for the assignee):

goldMedal William M Winston, Jr (29 out of 29 patents)

silverMedal Jeno Gyuris (29 out of 29 patents)

bronzeMedal Lyne Breault (17 out of 17 patents)

4.  Solly Weiler (14 out of 14 patents)

5.  Ting Chen (13 out of 80 patents)

6.  Jie Lin (12 out of 13 patents)

7.  Kristan Meetze (11 out of 13 patents)

8.  May Han (11 out of 11 patents)

9.  Lorena Lerner (10 out of 10 patents)

10.  Sylvie Vincent (9 out of 9 patents)

11.  S Kirk Wright (9 out of 9 patents)

12.  Bijan Etemad-Gilbertson (9 out of 10 patents)

13.  Christine Knuehl (9 out of 9 patents)

14.  Sandra Abbott (8 out of 8 patents)

15.  Steve Bottega (8 out of 8 patents)


Core Competencies:
GDF15 Modulators
ErbB3 Antibodies
Anti-Notch3 Antibodies
Tivozanib
Chronic Kidney Disease
Tumor Response Prediction
HGF Binding Proteins
Cancer Drug Discovery
Reconstituted Tumor Models
EMT Gene Signatures
FGFR2 Antibodies
RON Antibodies

42 patents:

1. 12703741 - TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR (2026-08-11),
2. 12486332 - ANTI-ERBB3 ANTIBODIES (2025-12-02),
3. 12338282 - Anti-Notch3 antibody (2025-06-24),
4. 12269877 - Anti-notch3 antibodies (2025-04-08),
5. 12258391 - Anti-GDF-15 antibodies (2025-03-25),
6. 11897948 - Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator (2024-02-13),
7. 11725047 - Anti-GDF-15 antibodies (2023-08-15),
8. 11680108 - Anti-ErbB3 antibodies (2023-06-20),
9. 11504365 - Use of tivozanib to treat subjects with refractory cancer (2022-11-22),
10. 11142573 - Anti-Notch3 antibody (2021-10-12),
11. 10745476 - Anti-NOTCH3 antibodies (2020-08-18),
12. 10597444 - Anti-GDF15 antibodies (2020-03-24),
13. 10494441 - Anti-ERBB3 antibodies (2019-12-03),
14. 9896730 - Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment (2018-02-20),
15. 9879083 - Anti-Notch3 antibodies (2018-01-30),
Company Overview
Aveo Pharmaceuticals, Inc., based in Cambridge, MA, specializes in the development of innovative therapies for cancer and chronic kidney disease. The company focuses on advancing its proprietary antibody technologies, including Anti-Notch3 and Anti-GDF-15 antibodies, to address unmet medical needs in refractory cancer treatment. Additionally, Aveo is engaged in cancer drug discovery, leveraging insights into key growth factors such as Hepatocyte Growth Factor and Fibroblast Growth Factor Receptor to create targeted therapeutic solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Aveo Pharmaceuticals, Inc. USPTO Patent Assignee Logo
42 Patents

#69 in Cambridge, MA

#481 in Massachusetts

#8,258 in US

#16,354 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Aveo Pharmaceuticals, Inc.

Forward Citations = 163

71 inventors:

goldMedal William M Winston, Jr (29 out of 29 patents)

silverMedal Jeno Gyuris (29 out of 29 patents)

bronzeMedal Lyne Breault (17 out of 17 patents)

4.  Solly Weiler (14 out of 14 patents)

5.  Ting Chen (13 out of 80 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aveo Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/aveo-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…